AVNT Q3 2023: Margin Expansion Offsets 15% Volume Decline as Europe Turns Positive
AVNT delivered margin gains despite a steep volume drop, as Europe’s turnaround and cost actions drove a 12% Q4 EPS growth outlook. Healthcare destocking and weak demand weighed on sales, but improved mix and raw material tailwinds supported earnings. Management signals a return to growth in 2024 as end-market headwinds ease and specialty initiatives gain traction.
Summary
- Margin Expansion Outpaces Volume Weakness: Cost reductions and favorable mix offset lower sales, driving earnings growth.
- Europe Returns to Profit Growth: Restructuring and raw material deflation make EMEA a bottom-line contributor again.
- Sustainable Solutions and Composites Set Up 2024: Management sees destocking ending, positioning AVNT for renewed growth next year.
Business Overview
AVNT is a specialty materials company, generating revenue through the design, production, and sale of advanced polymers, colorants, additives, and composites. Its major segments include Specialty Engineered Materials (SEM), Sustainable Solutions, and Protective Materials, with key end markets in packaging, healthcare, building and construction, defense, and consumer applications. The company’s business model relies on providing high-performance, often custom-formulated materials that address customer needs in sustainability, durability, and regulatory compliance.
Performance Analysis
AVNT’s third quarter was marked by a 15% volume decline and a sales shortfall, as ongoing destocking in healthcare and rate-sensitive sectors weighed on demand. Despite this, adjusted EBITDA margins expanded by 90 basis points year-over-year to 16.3%, reflecting the impact of cost reductions, lower raw materials, and favorable mix from defense and sustainable solutions. The company’s EPS slightly exceeded guidance due to lower depreciation and interest expense, aided by debt paydown and refinancing.
Europe, previously a drag, returned to positive EBITDA growth for the first time in a year, thanks to footprint rationalization and administrative cost cuts. The integration of Dyneema, protective materials acquisition, continues to open new cross-selling and margin opportunities. Healthcare sales, historically resilient, fell 25% due to inventory normalization, but management expects underlying demand to remain intact. Packaging, AVNT’s largest end market, is showing signs of stabilization, with customers shifting from inventory reduction to management, suggesting a potential inflection in early 2024.
- Healthcare Destocking Pressure: OEM customers’ inventory remains elevated at 80% of sales, versus 60% pre-pandemic, extending destocking into 2024.
- Cost Actions Drive Results: $13 million in quarterly savings from European restructuring and discretionary spend cuts supported margin gains.
- Raw Material Deflation Tailwind: Second consecutive quarter of net benefit from falling input costs, with price discipline holding firm.
Free cash flow guidance remains unchanged, underpinned by working capital efficiency and reduced capex. Management’s proactive price management and specialty mix have insulated margins in a challenging demand environment.
Executive Commentary
"While we have adjusted our revenue projections, you'll see that we are expecting to grow fourth quarter earnings by 12% on a year-over-year basis as margin expansion more than offsets lower sales."
Bob Patterson, Chairman, President, and Chief Executive Officer
"Third quarter adjusted EBITDA margins were 16.3% compared to our guidance of 16%. This reflects a 90 basis point improvement over the prior year. As has been the case all year, we have been able to partially offset weaker demand conditions with favorable mix from sustainable solutions and defense applications, which has proven resilient in the current environment."
Jamie Beggs, Senior Vice President and Chief Financial Officer
Strategic Positioning
1. Specialty Portfolio Resilience
AVNT’s strategic shift toward specialty materials—including composites, sustainable solutions, and protective materials—continues to pay off. These higher-margin businesses now make up 60% of sales, supporting both earnings stability and long-term growth targets of 6% annually. The Dyneema acquisition expands AVNT’s reach into defense and law enforcement, diversifying end-market exposure and enabling cross-selling opportunities.
2. European Turnaround and Cost Discipline
Europe’s return to EBITDA growth is a direct result of aggressive restructuring, footprint rationalization, and cost control. Administrative cost reductions and lower raw materials have restored profitability, and management expects EMEA to be a significant contributor to Q4 and 2024 results. This is a critical pivot for a region that had been a drag on group performance.
3. Raw Material and Pricing Leverage
AVNT’s ability to maintain pricing while benefiting from raw material deflation has provided a margin cushion in a weak demand environment. The company’s value-added positioning allows for price stability even as input costs fall, and management views current raw material trends as a continued tailwind into the first half of 2024.
4. End-Market Diversification and Megatrend Alignment
Exposure to secular growth drivers—such as sustainability mandates, infrastructure stimulus, and reshoring—positions AVNT to capitalize on long-term demand. Initiatives like the Broadband Equity Access and Deployment Program and the Inflation Reduction Act are expected to boost composite applications, while customer sustainability goals drive adoption of AVNT’s advanced formulations.
Key Considerations
This quarter underscores the importance of AVNT’s specialty focus and cost flexibility as volume headwinds persist. The business is navigating a complex environment with a blend of cyclical and secular forces.
Key Considerations:
- Healthcare Inventory Overhang: Destocking in healthcare, typically a growth engine, is expected to persist into 2024, but underlying demand remains positive.
- Packaging Stabilization Signals: Largest end market shows signs of bottoming, with customers shifting from inventory reduction to management, setting up for a potential rebound in 2024.
- European Execution: Cost actions and restructuring have restored profitability, providing a template for margin improvement in other regions.
- Specialty Mix and Innovation: Dyneema integration and cross-selling are expanding AVNT’s reach in defense and consumer applications, supporting premium margins.
- Cash Flow and Capital Allocation: Consistent free cash flow and a 13th consecutive dividend increase highlight disciplined capital management.
Risks
Persistent demand weakness in healthcare and interest rate-sensitive sectors remains a risk, with visibility on order trends still limited to 30-40 days. Foreign exchange volatility and further macroeconomic deterioration could pressure reported results, especially in Europe and Asia. While cost actions have supported margins, volume recovery is needed for sustainable growth. The pace and magnitude of destocking normalization, particularly in healthcare, is uncertain and could weigh on 2024 performance if slower than anticipated.
Forward Outlook
For Q4, AVNT guided to:
- Adjusted EBITDA of $112 million
- Adjusted EPS of $0.47, up 12% year-over-year
For full-year 2023, management lowered guidance to:
- Revenue of $3.13 billion
- Adjusted EBITDA of $500 million
- Adjusted EPS of $2.30
- Free cash flow maintained at $180 million
Management highlighted several factors that will influence 2024:
- Destocking in healthcare and packaging nearing completion, with early signs of stabilization.
- Raw material deflation and cost actions expected to support margins in the first half.
- Seasonal Q1 strength in Europe anticipated, with margin momentum carrying into next year.
Takeaways
AVNT’s specialty pivot and cost actions have preserved earnings power in a tough volume environment, with Europe’s turnaround and raw material tailwinds positioning the company for a return to growth in 2024.
- Margin Leverage: Structural cost reductions and specialty mix have offset steep volume declines, demonstrating business model resilience.
- Strategic Progress: Dyneema integration and focus on sustainable solutions are expanding addressable markets and supporting premium margin targets.
- 2024 Watchpoints: Investors should monitor the pace of healthcare and packaging recovery, raw material trends, and execution on specialty growth initiatives for confirmation of a sustained upturn.
Conclusion
AVNT’s Q3 results highlight a successful margin defense amid significant volume and sales headwinds, as specialty positioning and disciplined execution drive bottom-line stability. With destocking nearing an end and Europe contributing positively, the company is poised to exit 2023 with earnings momentum and a foundation for renewed growth in 2024.
Industry Read-Through
AVNT’s experience this quarter reflects broader materials sector themes: persistent destocking in healthcare and packaging, margin outperformance driven by cost actions, and the growing importance of specialty and sustainable solutions. The return of EBITDA growth in Europe signals that aggressive restructuring can restore profitability even in challenged regions. For peers, the ability to hold price and benefit from raw material deflation is a key differentiator in a low-demand environment. The pace of recovery in healthcare and the durability of raw material tailwinds will be critical watchpoints for the specialty chemicals and engineered materials industry heading into 2024.